US5726147A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human mutant tissue factor compositions useful as tissue factor antagonists
Assignee: Scripps Research Institute
•
Filing: 1994-06-01
•
Granted: 1998-03-10
•
Expires: 2014-06-01
Abstract
Abstract The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.
Inventors
- 👤 Wolfram Ruf
- 👤 Thomas S. Edgington
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:13
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; C07K14/745; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
82 words
A mutant human tissue factor protein (mhuTF) having the capacity to bind Factor VII/VIIa and having at least a 40 percent reduced tissue factor procoagulant cofactor activity, wherein said protein comprises the amino acid residue sequence shown in SEQ ID NO 2 from residues 1-218 and includes at least one amino acid residue substitution selected from the group consisting of A16, A17, A39, A40, A42, A44, E44, R44, A67, A104, A105, A106, A131, A136, A145, A146, A147, A198, A199, A200 and A201.
Claim 2
Dependent Claim
82 words
A mutant human tissue factor protein (mhuTF) having the capacity to bind Factor VII/VIIa and having at least a 40 percent reduced tissue factor procoagulant cofactor activity, wherein said protein comprises the amino acid residue sequence shown in SEQ ID NO 2 from residues 1-218 and includes at least one amino acid residue substitution selected from the group consisting of A16, A17, A39, A40, A42, A44, E44, R44, A67, A104, A105, A106, A131, A136, A145, A146, A147, A198, A199, A200 and A201.
Claim 3
Dependent Claim
20 words
The mutant human tissue factor protein of claim 1 wherein said protein has, the three substitutions A39, A40 and A42.
Claim 4
Dependent Claim
19 words
The mutant human tissue factor protein of claim 1 wherein said protein has the two substitutions A103 and A104.
Claim 5
Dependent Claim
19 words
The mutant human tissue factor protein of claim 1 wherein said protein has the two substitutions A139 and A142.
Claim 6
Dependent Claim
19 words
The mutant human tissue factor protein of claim 1 wherein said protein has the two substitutions A200 and A201.
Claim 7
Dependent Claim
24 words
The mutant human tissue factor protein of claim 1 wherein said protein has at least a 75 percent reduced tissue factor procoagulant cofactor activity.
Claim 8
Dependent Claim
30 words
The mutant human tissue factor protein of claim 1 wherein said protein is a soluble protein which lacks a membrane anchor shown in SEQ ID NO 2 at residues 219-263.
Claim 9
Dependent Claim
30 words
The mutant human tissue factor protein of claim 1 wherein said protein is a membrane-associated protein including a membrane anchor as shown in SEQ ID NO 2 from residues 219-263.
Claim 10
Dependent Claim
29 words
A therapeutic composition for inhibiting human tissue factor (huTF) comprising a pharmaceutically acceptable carrier and a therapeutic amount of a mutant human tissue factor protein according to claim 1.
Claim 11
Dependent Claim
23 words
The composition of claim 9 wherein said mhuTF protein is a membrane-associated protein including a membrane anchor and said composition further comprising liposomes.
Claim 12
Dependent Claim
22 words
The composition of claim 9 further comprising a carbohydrate cryopreservative selected from a group consisting of trehalose, maltose, lactose, glucose, and mannitol.
Claim 13
Dependent Claim
9 words
The composition of claim 9 further comprising a detergent.
Claim 14
Dependent Claim
20 words
The composition of claim 12 wherein said detergent is selected from the group consisting of octyl beta-D-glucopyranoside and octyl beta-D-thioglucopyranoside.
Claim 15
Dependent Claim
29 words
A method for inhibiting human tissue factor procoagulant activity associated with Factor VII/VIIa comprising contacting said Factor VII/VIIa with a mutant human tissue factor protein according to claim 1.
Claim 16
Dependent Claim
30 words
The method of claim 14 wherein said Factor VII/VIIa is present in a sample and said contacting is conducted by admixing said mutant human tissue factor protein with said sample.
Claim 17
Dependent Claim
39 words
The method of claim 14 wherein said Factor VII/VIIa is present in a body fluid of a human patient and said contacting is conducted by administering said mutant human tissue factor protein to said body fluid of said patient.
Claim 18
Dependent Claim
31 words
The method of claim 14 wherein said amount is an amount sufficient to subject said Factor VII/VIIa to from about 1 picomolar to about 100 nanomolar mutant human tissue factor protein.
References Cited (Backward Citations)
US5288629A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-03-09 | 2001-09-08 | 2002-03-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-03-09 | 2005-09-08 | 2006-03-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-03-09 | 2009-09-08 | 2010-03-10 | $7700.00 | Window Closed / Lapsed |